Lifileucel

DB17107ApprovedInvestigationalCell transplant therapies

Lifileucel is an autologous T cell immunotherapy used to treat unresectable or metastatic melanoma in previously treated adults. A cancer therapy made up of immune cells used to treat specific types of skin cancer in adults.

Mechanism: The exact mechanism of action of lifileucel has not been fully elucidated. Lifileucel is composed of autologous tumour-infiltrating lymphocytes (TILS) that once administered, recognize tumour antigens and promote tumour cell lysis.
Curator reviewed · 2 references
Primary indication: Lifileucel is indicated for the treatment of adult patients with unresectable or metastatic melanoma previously treated with a PD-1 blocking antibody, and if BRAF V600 mutation-positive, a BRAF inhibitor with or without a MEK inhibitor.Curator reviewed · 4 structured indications
First approval: Canada, 2025 · United States, 2024
Code names: LN - 144 · LN-145
Brand names: Amtagvi

Resolves to

Compound

UNIIR0835E18NHCAS2306267-74-1

Clinical / RWD

RxNorm2675860ATCL01XL11

What you can answer from here — as of March 26, 2026

38Drug interactionsStructured to mechanism, not free text

39Clinical trialsPhase, status and sponsor resolved per trial

4Structured indicationsCondition, population, route and combination as fields, not prose

2Marketed productsAcross 2 countries and 1 labeller

1ATC codeIncluding every combination product, plus 6 drug categories

4+ReferencesStructured and connected to the statements they support

Which other approved drugs treat the same conditions as Lifileucel, and which companies have late-stage candidates in those indications?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account